Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) posted its earnings results on Wednesday. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $1.12, Bloomberg Earnings reports.
Shares of Anthera Pharmaceuticals (ANTH) traded down 6.85% during midday trading on Thursday, hitting $1.36. The stock had a trading volume of 1,000,268 shares. Anthera Pharmaceuticals has a one year low of $0.30 and a one year high of $3.55. The stock’s market cap is $13.70 million. The firm has a 50 day moving average price of $1.53 and a 200 day moving average price of $1.13.
WARNING: “Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Issues Quarterly Earnings Results” was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/2798354/anthera-pharmaceuticals-inc-nasdaqanth-issues-quarterly-earnings-results.html.
ANTH has been the topic of several analyst reports. Zacks Investment Research lowered Anthera Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 8th. ValuEngine lowered Anthera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $2.25 target price on shares of Anthera Pharmaceuticals in a research note on Monday, May 15th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $10.21.
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.